The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
 
Hirokazu Shoji
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Gakuto Ogawa
No Relationships to Disclose
 
Mamiko Kawasaki
Stock and Other Ownership Interests - Astellas Pharma
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Mikio Mori
Employment - Daiichi Sankyo; Sanwa Kagaku Kenkyusho (I)
Stock and Other Ownership Interests - Daiichi Sankyo; Daiichi Sankyo (I)
 
Yoshitaka Honma
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai/Roche; Daiichi Sankyo; Merck Serono; Novelpharm; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Natsuko Okita
No Relationships to Disclose
 
Yasuhide Yamada
Honoraria - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai; Janssen
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Takeda (Inst)